Does hormone receptor status influence the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer?
Among patients with HR+/HER2+ disease, treatment with trastuzumab reduces LRR risk to the more favorable outcome of patients with HR+/HER2- disease. In contrast, the increased LRR risk among patients with HR-/HER2+ disease remains despite treatment with trastuzumab. Additional locoregional strategies are needed in this subgroup of patients.
Detection of endoscopic and histological inflammation after attack of AUD was identified as a predictor of diverticulitis recurrence.